BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Dajani AI, Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. World J Clin Cases 2020; 8(21): 5235-5249 [PMID: 33269259 DOI: 10.12998/wjcc.v8.i21.5235]
URL: https://www.wjgnet.com/1007-9327/full/v8/i21/5235.htm
Number Citing Articles
1
L. B. Lazebnik, E. V. Golovanova, S. V. Turkina, K. L. Raikhelson, S. V. Okovityy, O. M. Drapkina, I. V. Maev, A. I. Martynov, G. E. Roitberg, O. V. Khlynova, D. I. Abdulganieva, S. A. Alekseenko, M. D. Ardatskaya, I. G. Bakulin, N. V. Bakulina, A. O. Bueverov, E. V. Vinitskaya, G. V. Volynets, E. Yu. Eremina, V. B. Grinevich, A. I. Dolgushina, A. N. Kazyulin, E. I. Kashkina, I. V. Kozlova, Yu. V. Konev, N. V. Korochanskaya, Yu. A. Kravchuk, E. D. Li, I. D. Loranskaya, V. M. Makhov, S. N. Mekhtiev, V. P. Novikova, O. D. Ostroumova, Ch. S. Pavlov, V. G. Radchenko, A. A. Samsonov, A. S. Sarsenbaeva, R. G. Sayfutdinov, P. V. Seliverstov, S. I. Sitkin, O. V. Stefanyuk, L. V. Tarasova, E. I. Tkachenko, Yu. P. Uspensky, Yu. A. Fominykh, A. I. Khavkin, Yu. V. Tsyganova, O. O. Sharhun. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third versionExperimental and Clinical Gastroenterology 2021; 1(1): 4 doi: 10.31146/1682-8658-ecg-185-1-4-52
2
Asad Izziddin Dajani, Adnan Abuhammour. Agents for the treatment of fatty liver disease: focus on essential phospholipidsDrugs & Therapy Perspectives 2021; 37(6): 249 doi: 10.1007/s40267-021-00838-x
3
Daria A. Teplyuk, Aliya A. Kaisina, Shabnam I. Ibragimova, Afina A. Bestavashvili, Irina O. Tinkova, Evgeniia Iu. Pashkova, Jamilya A. Kaibullayeva, Alexander V. Nersesov, Chavdar S. Pavlov. Non-alcoholic fatty liver disease: from understanding risk factors to finding optimal treatment regimens: A reviewConsilium Medicum 2023; 25(5): 325 doi: 10.26442/20751753.2023.5.202272
4
Inês Domingues, Hafsa Yagoubi, Wunan Zhang, Valentina Marotti, Espoir K. Kambale, Katlijn Vints, Malgorzata Alicja Sliwinska, Isabelle A. Leclercq, Ana Beloqui. Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver diseaseDrug Delivery and Translational Research 2024;  doi: 10.1007/s13346-024-01576-z
5
V. A. Prikhodko, S. V. Okovityi. Pharmacodynamic and pharmacokinetic aspects of combined use of glycyrrhizinic acidExperimental and Clinical Gastroenterology 2023; (8): 141 doi: 10.31146/1682-8658-ecg-216-8-141-150
6
VIKTOR TOMCHUK, ANDRII POTOTSKYI, VIKTORIIA GRYSHCHENKO, STANISLAV VESELSKYI, YEVDOKIIA RESHETNIK. CORRECTION OF TRIACYLGLYCEROLS AND FREE FATTY ACIDS IN RAT BILE IN EXPERIMENTAL HEPATIC STEATOSISUkrainian journal of veterinary sciences 2022; 13(2) doi: 10.31548/ujvs.13(2).2022.53-62
7
Inês Domingues, Isabelle A. Leclercq, Ana Beloqui. Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug deliveryJournal of Controlled Release 2023; 363: 415 doi: 10.1016/j.jconrel.2023.09.040
8
V. A. Gryshchenko, O. О. Danchenko, S. A. Tkachuk, T. I. Fotina, V. V. Zazharskyi, V. V. Brygadyrenko. Lipid composition of blood plasma and epithelium of the jejunal mucosa in calves with dyspepsia and its correction Regulatory Mechanisms in Biosystems 2023; 14(2): 319 doi: 10.15421/022347
9
E. V. Biryukova. Non-alcoholic fatty liver disease: a current challenge of interdisciplinary researchMeditsinskiy sovet = Medical Council 2024;  doi: 10.21518/ms2024-159
10
Ekaterina Demicheva, Vladislav Dordiuk, Fernando Polanco Espino, Konstantin Ushenin, Saied Aboushanab, Vadim Shevyrin, Aleksey Buhler, Elena Mukhlynina, Olga Solovyova, Irina Danilova, Elena Kovaleva. Advances in Mass Spectrometry-Based Blood Metabolomics Profiling for Non-Cancer Diseases: A Comprehensive ReviewMetabolites 2024; 14(1): 54 doi: 10.3390/metabo14010054
11
Ki M. Mak, Aditya C. Shekhar. Soybean polyenylphosphatidylcholine (PPC) is beneficial in liver and extrahepatic tissue injury: An update in experimental researchThe Anatomical Record 2023;  doi: 10.1002/ar.25333
12
D. A. Teplyuk, M. Ch. Semenistaya, S. M. Sorokoletov, L. B. Lazebnik, Ch. S. Pavlov. Nonalcoholic liver disease: review with a focus on risks of progressionExperimental and Clinical Gastroenterology 2021; (8): 167 doi: 10.31146/1682-8658-ecg-192-8-167-174
13
Sergey V. Okovityi, Karina L. Raikhelson, Veronika A. Prikhodko. Combined hepatoprotective pharmacotherapy for liver diseaseExperimental and Clinical Gastroenterology 2022; (7): 5 doi: 10.31146/1682-8658-ecg-203-7-5-20
14
Ludovico Abenavoli, Giuseppe La Torre, Natasa Milic. Comment on Clayton-Chubb et al. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients 2023, 15, 687Nutrients 2023; 15(13): 2907 doi: 10.3390/nu15132907
15
Dominik Wupperfeld, Gert Fricker, Béatrice Bois De Fer, Larissa Frank, Annika Wehrle, Branko Popovic. Essential phospholipids decrease apoptosis and increase membrane transport in human hepatocyte cell linesLipids in Health and Disease 2022; 21(1) doi: 10.1186/s12944-022-01698-8
16
Marek Hartleb, Agnieszka Mastalerz-Migas, Piotr Kowalski, Bogusław Okopień, Branko Popovic, Katarzyna Proga, Beata Cywińska-Durczak. Healthcare practitioners’ diagnostic and treatment practice patterns of nonalcoholic fatty liver disease in Poland: a cross-sectional surveyEuropean Journal of Gastroenterology & Hepatology 2022; 34(4): 426 doi: 10.1097/MEG.0000000000002288
17
Vladimir T. Ivashkin, Marina V. Maevskaya, Elena N. Shirokova, Igor V. Maev, Alexey A. Samsonov, Evgeniy I. Sas, Liudmila K. Palgova, Kirill Starostin. Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational StudiesDrugs - Real World Outcomes 2021; 8(3): 369 doi: 10.1007/s40801-021-00250-x
18
Stanislav Veselskyi, Andrii Pototskyi, Viktor Tomchuk, Viktoriia Gryshchenko, Yevdokiia Reshetnik. Phospholipid composition of bile and blood in rats under correction of experimental fatty hepatosisUkrainian journal of veterinary sciences 2023; 14(3): 25 doi: 10.31548/veterinary3.2023.25
19
Tatiana Y. Demidova, Fatima O. Ushanova. Non-alcoholic fatty liver disease: aspects of management of a comorbid patient. A reviewTerapevticheskii arkhiv 2023; 95(10): 888 doi: 10.26442/00403660.2023.10.202435
20
D. Osipova, K. Kokoreva, L. Lazebnik, E. Golovanova, Ch. Pavlov, A. Dukhanin, S. Orlova, K. Starostin. Regression of Liver Steatosis Following Phosphatidylcholine Administration: A Review of Molecular and Metabolic Pathways InvolvedFrontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.797923
21
Hui Peng, Jiangyuan Li, Huiting Xu, Xian Wang, Leya He, Naomi McCauley, Ke K. Zhang, Linglin Xie. Offspring NAFLD liver phospholipid profiles are differentially programmed by maternal high-fat diet and maternal one carbon supplementThe Journal of Nutritional Biochemistry 2023; 111: 109187 doi: 10.1016/j.jnutbio.2022.109187